Emerging Business Models in the Pharmaceutical Industries ...

More documents

Recommendations

Info

Contact Us For more information on our services and products contact us on: JSB Intelligence Kildare House, 102-104 Sheen Road Richmond, TW9 1UF United Kingdom. Tel. +44 (0) 870 7653 632 Fax. +44 (0) 870 7653 722 Email: sales@jsbintelligence.com Strategic Analysis of the Pharma Market, Future Revenue Models and Key Players 82
Page 1 and 2:
Emerging Business Models in the Pha
Page 3 and 4:
Table of Contents Introduction…
Page 5 and 6:
Acronyms Big Pharmas The top global
Page 7 and 8:
Introduction Pharma Industry Overvi
Page 9 and 10:
Market Segmentation Getting Blurred
Page 11 and 12:
Growth in the Pharma Market The pha
Page 13 and 14:
Factors Restraining Pharma Market R
Page 16 and 17:
Geographic Overview Introduction No
Page 18 and 19:
Trends in the Pharma Industry Short
Page 20 and 21:
Long Term Strategies - Forward Inte
Page 22 and 23:
Long Term Strategies - Targeted Tre
Page 24 and 25:
Long Term Strategies - Biotech and
Page 26 and 27:
Long Term Strategies - Biotech and
Page 28 and 29:
Overview of the Network Model The n
Page 30 and 31:
Outsourcing The network approach al
Page 32 and 33: Many of BMS's key drugs are from ot
Page 34 and 35: Growth in Semi Block Busters Even i
Page 36 and 37: Short Term Strategies - Pre- and Po
Page 38 and 39: Short Term Strategies Against Paral
Page 40 and 41: There are two main types of M&Q act
Page 42 and 43: The Revenue Model The market dynami
Page 44 and 45: Short Term and Mid Term Strategies
Page 46 and 47: Top 10 Pharma Companies - Major Mar
Page 48 and 49: Benchmarking - Top 20 Drugs by Sale
Page 50 and 51: Benchmarking by Percentage Growth i
Page 52 and 53: Benchmarking by Geographic Revenue
Page 54 and 55: Rank 1 2 3 4 5 JnJ GSK Company Pfiz
Page 56 and 57: Altace® Biaxin® Zofran® Brands A
Page 58 and 59: Introduction Pfizer is the world's
Page 60 and 61: Introduction GlaxoSmithKline (GSK)
Page 62 and 63: Introduction Merck & Co. develops,
Page 64 and 65: Introduction Aventis’ core busine
Page 66 and 67: Introduction Bristol-Myers Squibb C
Page 68 and 69: Strategic Direction The company aim
Page 70 and 71: Strategic Direction JnJ has been fo
Page 72 and 73: 15% Percentage Revenues by Segment
Page 74 and 75: 12 10 8 6 4 2 0 The Americas Revenu
Page 76 and 77: 20 15 10 5 0 Novartis revenues by S
Page 78 and 79: Strategic Direction Eli Lilly focus
Page 80 and 81: New Revenue Models New revenue mode
show all

Emerging Business Models in the Pharmaceutical Industries ...

Create successful ePaper yourself

Delete template?

Save as template?